Outlook Therapeutics issues unregistered warrants for 16,129,033 shares at $0.31 each

• Outlook Therapeutics set concurrent private placement of unregistered warrants to buy up to 16,129,033 shares at USD 0.31 per share.
• Warrants become exercisable after stockholder approval of underlying share issuance plus effective charter amendment to increase authorized shares.
• Expiration set for five years from later of first exercisable date or effective date of resale registration statement for warrant shares.
• Company agreed to amend 2,142,854 outstanding warrants, cutting exercise price to USD 0.31 from USD 2.26.
• Amended warrants become exercisable upon stockholder approval, expiring five years from that approval date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220830PRIMZONEFULLFEED9694875) on April 22, 2026, and is solely responsible for the information contained therein.